Literature DB >> 19104845

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

Sebastiano Mercadante1, Alessandra Casuccio, Walter Tirelli, Antonello Giarratano.   

Abstract

INTRODUCTION: The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control. MATERIALS, METHODS, AND
RESULTS: Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakthrough medication were recorded before switching (T0), 3 days after (T3), and 6 days after (T6). Eleven patients were recruited in a period of 1 year, and data were complete for ten patients. The mean age was 61.6 (SD 9.5), and five patients were males. No significant changes in pain and symptom intensity were found, except improvement in reported constipation (p = 0.014), as well as in global satisfaction with the analgesic treatment. No significant changes in breakthrough pain medication were observed.
CONCLUSION: The results of this study suggest that stable patients receiving relatively high doses of oral morphine or TD fentanyl could be safely switched to TD BUP, by using a ratio of 70:1 and 0.6:0.8, respectively, maintaining the same level of analgesia.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19104845     DOI: 10.1007/s00520-008-0546-6

Source DB:  PubMed          Journal:  Support Care Cancer        ISSN: 0941-4355            Impact factor:   3.603


  10 in total

1.  Challenging the equipotency calculation for transdermal buprenorphine: four case studies.

Authors:  R Likar; B Krainer; R Sittl
Journal:  Int J Clin Pract       Date:  2008-01       Impact factor: 2.503

2.  Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study.

Authors:  Reinhard Sittl; Rudolf Likar; Barbara Poulsen Nautrup
Journal:  Clin Ther       Date:  2005-02       Impact factor: 3.393

3.  Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

Authors:  Sebastiano Mercadante; Patrizia Villari; Patrizia Ferrera; Giampiero Porzio; Federica Aielli; Lucilla Verna; Alessandra Casuccio
Journal:  J Pain Symptom Manage       Date:  2006-08       Impact factor: 3.612

Review 4.  Buprenorphine in cancer pain.

Authors:  Mellar P Davis
Journal:  Support Care Cancer       Date:  2005-07-12       Impact factor: 3.603

5.  Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain.

Authors:  Thomas Christoph; Babette Kögel; Klaus Schiene; Murielle Méen; Jean De Vry; Elmar Friderichs
Journal:  Eur J Pharmacol       Date:  2004-12-30       Impact factor: 4.432

6.  Opioid rotation from high-dose morphine to transdermal buprenorphine (Transtec) in chronic pain patients.

Authors:  Enno Freye; Astrid Anderson-Hillemacher; Ingrid Ritzdorf; Joseph Victor Levy
Journal:  Pain Pract       Date:  2007-06       Impact factor: 3.183

7.  Switching from transdermal drugs: an observational "N of 1" study of fentanyl and buprenorphine.

Authors:  Sebastiano Mercadante; Giampiero Porzio; Fabio Fulfaro; Federica Aielli; Lucilla Verna; Corrado Ficorella; Alessandra Casuccio; Salvatore Riina; Giuseppe Intravaia; Salvatore Mangione
Journal:  J Pain Symptom Manage       Date:  2007-07-16       Impact factor: 3.612

8.  Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial.

Authors:  Reinhard Sittl; Norbert Griessinger; Rudolf Likar
Journal:  Clin Ther       Date:  2003-01       Impact factor: 3.393

9.  Is there a ceiling effect of transdermal buprenorphine? Preliminary data in cancer patients.

Authors:  Sebastiano Mercadante; Patrizia Ferrera; Patrizia Villari
Journal:  Support Care Cancer       Date:  2006-11-15       Impact factor: 3.359

10.  Morphine and alternative opioids in cancer pain: the EAPC recommendations.

Authors:  G W Hanks; F Conno; N Cherny; M Hanna; E Kalso; H J McQuay; S Mercadante; J Meynadier; P Poulain; C Ripamonti; L Radbruch; J R Casas; J Sawe; R G Twycross; V Ventafridda
Journal:  Br J Cancer       Date:  2001-03-02       Impact factor: 7.640

  10 in total
  12 in total

1.  Successful use of buprenorphine-naloxone medication-assisted program to treat concurrent pain and opioid addiction after cancer therapy.

Authors:  Natalie Moryl; Alexandra Filkins; Yvona Griffo; Vivek Malhotra; Raina H Jain; Ethel Frierson; Charles Inturrisi
Journal:  J Opioid Manag       Date:  2020 Mar/Apr

Review 2.  Buprenorphine for treating cancer pain.

Authors:  Mia Schmidt-Hansen; Nathan Bromham; Mark Taubert; Stephanie Arnold; Jennifer S Hilgart
Journal:  Cochrane Database Syst Rev       Date:  2015-03-31

Review 3.  Options for Treating Pain in Cancer Patients with Dysphagia.

Authors:  Sebastiano Mercadante
Journal:  Drugs       Date:  2017-04       Impact factor: 9.546

Review 4.  Treating Chronic Pain: An Overview of Clinical Studies Centered on the Buprenorphine Option.

Authors:  Mellar P Davis; Gavril Pasternak; Bertrand Behm
Journal:  Drugs       Date:  2018-08       Impact factor: 9.546

Review 5.  Treating Chronic Pain with Buprenorphine-The Practical Guide.

Authors:  Amy A Case; Justin Kullgren; Sidra Anwar; Sandra Pedraza; Mellar P Davis
Journal:  Curr Treat Options Oncol       Date:  2021-11-18

6.  Reporting characteristics of cancer pain: a systematic review and quantitative analysis of research publications in palliative care journals.

Authors:  Senthil P Kumar
Journal:  Indian J Palliat Care       Date:  2011-01

7.  Transdermal buprenorphine - a critical appraisal of its role in pain management.

Authors:  Guy Hans; Dominique Robert
Journal:  J Pain Res       Date:  2009-09-15       Impact factor: 3.133

8.  Differences between Transdermal Fentanyl and Buprenorphine in the Elderly Hospice Patients.

Authors:  Marin Golčić; Renata Dobrila-Dintinjana; Goran Golčić; Lidija Gović-Golčić
Journal:  Pain Res Treat       Date:  2018-10-15

Review 9.  Dosing considerations with transdermal formulations of fentanyl and buprenorphine for the treatment of cancer pain.

Authors:  Tracy L Skaer
Journal:  J Pain Res       Date:  2014-08-19       Impact factor: 3.133

10.  Use of immediate-release opioids as supplemental analgesia during management of moderate-to-severe chronic pain with buprenorphine transdermal system.

Authors:  Sanford Silverman; Robert B Raffa; Marc J Cataldo; Monica Kwarcinski; Steven R Ripa
Journal:  J Pain Res       Date:  2017-05-24       Impact factor: 3.133

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.